The acute D-amphetamine model induces a hyperdopaminergic state by enhancing dopamine release and blocking reuptake, thereby modeling the dopamine hypothesis of schizophrenia. It produces robust behavioral deficits relevant to positive symptoms, including hyperlocomotion, stereotypy, and sensory processing disruptions such as impaired prepulse inhibition (PPI).

What you will find in this case study:

Pharmacological Validation with Clozapine

The study evaluates the effects of clozapine on D-amphetamine-induced hyperactivity and PPI deficits. Data demonstrate that clozapine effectively reverses both the locomotor activation and sensorimotor gating impairments induced by amphetamine, confirming the model's predictive validity for antipsychotic drug screening.

Key Endpoints: Locomotor Activity & Prepulse Inhibition

• Locomotor Activity

  Total distance traveled is quantified to assess drug-induced hyperactivity and its reversal by clozapine, providing a direct measure of antipsychotic efficacy on motor-related symptoms.

• Prepulse Inhibition (PPI):

  PPI disruption serves as a translational measure of sensorimotor gating deficits. The study presents PPI data showing that clozapine treatment restores gating function, underscoring its utility in evaluating compounds targeting both dopaminergic and broader receptor mechanisms.

Study Design & Reproducible Data

This case study clearly outlines the experimental design, including the species used (C57BL/6 mice and Sprague-Dawley rats), dosing regimens, behavioral testing protocols, and resulting data. These findings demonstrate model reliability and data reproducibility, supporting clients in making informed decisions during drug development.

Whether you are advancing a novel antipsychotic candidate, validating model systems, or seeking a trusted CRO partner with proven expertise in schizophrenia pharmacology, this case study demonstrates Ace Therapeutics' capabilities in acute schizophrenia model development and behavioral assessment.

Download the full case study to review the complete dataset and explore how our preclinical models can support your psychiatric drug development programs.

You might be interested in...